August 2024 Analysis of Türkiye’s Pharmaceutical Foreign Trade
By Melike Belenli Gümüş
October 17, 2024
The report titled August 2024 Pharmaceutical Industry Foreign Trade Analysis (Ağustos 2024 İlaç Endüstrisi Dış Ticaret Analizi), published by Pharmaceutical Industry Employers’ Association of Türkiye, provides a detailed analysis of Türkiye’s foreign trade, focusing particularly on the pharmaceutical industry. This “August 2024 Pharmaceutical Industry Foreign Trade Analysis” offers key insights into the performance and dynamics of Türkiyes’s pharmaceutical foreign trade within the context of its overall trade landscape.
General Foreign Trade
Over a 12-month period, Türkiye’s total exports increased by 3.5% compared to the previous period, reaching $261.8 billion.
Pharmaceutical Industry Trade
The report specifically highlights the performance of the pharmaceutical industry in foreign trade. Here are a few key metrics:
Import and Export Dynamics: The report likely includes an analysis of both import and export trends within the pharmaceutical sector, providing insights into the industry’s trade balance and key markets.
Export Performance: The pharmaceutical industry’s export figures are analysed in detail. In the first eight months of 2024, Türkiye’s pharmaceutical exports rose by 4.3% to 1.4907 billion USD, while imports increased by 4.9% to 3.9891 billion USD, resulting in a trade deficit of 2.4984 billion USD and a coverage ratio of 37.4%. Over 12 months, pharmaceutical exports grew by 4.4% to 2.29 billion USD, and imports rose by 5.8% to 5.9 billion USD, leading to a 3.6 billion USD trade deficit and a 38.6% coverage ratio.
Figure 1. Monthly Pharmaceutical Export and Import Values (million USD). Green bars indicate export, blue bars indicate import and dashed line indicates the coverage ratio of export-to-import.
Market and Product Analysis
The report includes an analysis of the main markets for Turkish pharmaceutical exports and imports, as well as the types of pharmaceutical products that are most traded. As of August 2024, South Korea, Hungary, and Iraq are the top three destinations for pharmaceutical exports from Türkiye, with Asia accounting for 45.3% of the export market. During the same period, 63.2% of pharmaceutical imports to Türkiye came from Europe, with the United States, Germany, and Ireland being the top three import sources.
Figure 2. Distribution of Exports by Countries (%).
Figure 3. Distribution of Imports by Countries (%).
Economic and Policy Context
The analysis might be set against the broader economic and policy context, including any government initiatives or global economic conditions that affect the pharmaceutical industry’s trade activities. A more detailed report discussing changes in market trends, regulatory impacts, and other factors influencing the pharmaceutical industry’s foreign trade would be beneficial for fully understanding the current situation of the pharmaceutical industry in Türkiye.
To fully grasp the insights presented within this “August 2024 Pharmaceutical Industry Foreign Trade Analysis,” it would be necessary to read the complete report, as the summary provided does not include all the specific details and data points covered in the analysis.
🌍 Are we on the brink of a new era in Hepatitis C treatment?
Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.
Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.
🔍 Is political influence undermining the integrity of scientific publishing?
In his thought-provoking article, Kamran Abbasi critiques the Trump administration’s attempts to shape medical literature, revealing serious methodological flaws and biases that could jeopardize scientific progress. This analysis emphasizes the need for transparency and rigor in research to ensure that political pressures do not compromise the quality of scientific discourse.
Curious to learn more about the implications for healthcare and the future of scientific publishing? Click to read the full article!
🔍 What does a recent court ruling mean for South Africa’s healthcare system?
This pivotal decision from the Gauteng High Court mandates President Cyril Ramaphosa to justify his signing of the National Health Insurance Bill, opening the door for judicial review of executive decisions in healthcare legislation. As the implications of this ruling unfold, it reflects a significant check on executive power, particularly in contentious policy areas.
Curious to learn more about the potential impact on the NHI Act and South Africa’s healthcare future? Dive into the full article for comprehensive insights!
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.
